Protara Therapeutics Stock In The News
| TARA Stock | USD 3.04 0.10 3.40% |
Our overall analysis of Protara Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Protara Therapeutics. The specific impact of Protara Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Protara Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Protara Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Protara Therapeutics Backtesting and Protara Therapeutics Hype Analysis. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.
Protara |
Protara Therapeutics Today Top News and Investor Outlook
Protara Therapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Protara and other traded companies coverage with news coverage. We help investors stay connected with Protara headlines for the 28th of November to make an informed investment decision based on correlating the impacts of news items on Protara Stock performance. Please note that trading solely based on the Protara Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Protara Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Protara earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Protara Therapeutics that are available to investors today. That information is available publicly through Protara media outlets and privately through word of mouth or via Protara internal channels. However, regardless of the origin, that massive amount of Protara data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Protara Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Protara Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Protara Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Protara Therapeutics alpha.
Protara Largest EPS Surprises
Earnings surprises can significantly impact Protara Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-11-03 | 2022-09-30 | -0.76 | -0.68 | 0.08 | 10 | ||
2021-03-11 | 2020-12-31 | -0.54 | -0.44 | 0.1 | 18 | ||
2023-11-03 | 2023-09-30 | -0.98 | -0.87 | 0.11 | 11 | ||
2023-08-03 | 2023-06-30 | -0.87 | -1.0 | -0.13 | 14 | ||
2022-08-09 | 2022-06-30 | -0.94 | -0.8 | 0.14 | 14 | ||
2024-08-06 | 2024-06-30 | -0.8 | -0.45 | 0.35 | 43 |
Protara Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Protara Therapeutics Stock. Current markets are slightly bullish. About 55% of major world exchanges and indexes are currently up. See today's market update for more information.
27th of November 2024
Global Human Growth Hormones Market to Reach USD 10 Billion by 2030 DelveInsight at finance.yahoo.com
18th of November 2024
Opaleye Management Inc. Reduces Stake in Protara Therapeutics Inc. - GuruFocus.com at news.google.com
13th of November 2024
Protara Therapeutics Reports Increased RD Expenses - TipRanks at news.google.com
8th of November 2024
Disposition of 2500 shares by Opaleye Management Inc. of Protara Therapeutics at 2.1233 su... at thelincolnianonline.com
30th of October 2024
Disposition of 3500 shares by Opaleye Management Inc. of Protara Therapeutics at 2.4419 su... at MacroaxisInsider
10th of October 2024
Cure Alzheimers Fund Receives 338,384 Donation from Tara Manufacturing at finance.yahoo.com
24th of September 2024
Variscite and Embedded Wizard by TARA Systems Integrate Advanced GUIs in SoMs to Speed Dev... at businesswire.com
10th of September 2024
Disposition of 1500 shares by Opaleye Management Inc. of Protara Therapeutics at 1.769 sub... at MacroaxisInsider
9th of September 2024
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of T... at globenewswire.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Protara Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Protara Therapeutics' short interest history, or implied volatility extrapolated from Protara Therapeutics options trading.
Check out Protara Therapeutics Backtesting and Protara Therapeutics Hype Analysis. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protara Therapeutics. If investors know Protara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Return On Assets (0.28) | Return On Equity (0.46) |
The market value of Protara Therapeutics is measured differently than its book value, which is the value of Protara that is recorded on the company's balance sheet. Investors also form their own opinion of Protara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protara Therapeutics' market value can be influenced by many factors that don't directly affect Protara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.